Ken Griffin
REVB icon

Ken Griffin’s Revelation Biosciences REVB Stock Holding History

Ken Griffin’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,682
Closed -$43.8K – 14025
2025
Q4 		$43.8K Buy
+13,682
New +$59.9K ﹤0.01% 12094
2024
Q1 		– Sell
-4
Closed -$12.1K – 15325
2023
Q4 		$12.1K Sell
4
-6
-60% -$21.4K ﹤0.01% 13009
2023
Q3 		$39K Buy
+10
New +$44.1K ﹤0.01% 12021
2022
Q4 		– Hold
0
– -$6K – 15355
2022
Q3 		– Hold
0
– – – 12350
2022
Q2 		– Hold
0
– -$49K – 13903
2022
Q1 		– Hold
0
– – – 12800

Other funds holding REVB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Ken Griffin's REVB Position: Q1 2026 in Review

Ken Griffin sold out of Revelation Biosciences (REVB) in Q1 2026, closing a stake of 13,682 shares — an estimated $43.8K sold.

Ken Griffin first reported a position in REVB in Q3 2023 and held it in 3 quarters. The position peaked at $43.8K in Q4 2025. 12 funds tracked by Wall St. Rank hold REVB as of Q1 2026.

  • Ken Griffin reported no remaining Revelation Biosciences position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 13,682 Revelation Biosciences shares in Q1 2026, an estimated $43.8K.
  • Ken Griffin first reported a position in Revelation Biosciences in Q3 2023 and held it in 3 quarters.
  • Ken Griffin's Revelation Biosciences position peaked at $43.8K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.